Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
The Food and Drug Administration (FDA) has expanded the approval of Breo Ellipta (fluticasone furoate and vilanterol inhalation powder) to include maintenance treatment of asthma in children 5 to 17 years of age. Previously, the product was only approved for maintenance treatment of asthma in adults.
Breo Ellipta is a fixed-dose combination of the inhaled corticosteroid (ICS) fluticasone furoate, and the long-acting beta2-agonist (LABA) vilanterol. The expanded approval was based on data from a 24-week, randomized, double-blind, parallel-group phase 3 trial (ClinicalTrials.gov Identifier: NCT03248128) that included pediatric asthma patients uncontrolled on their current ICS treatment.
Patients aged 12 to 17 years were randomly assigned to receive Breo Ellipta 100/25mcg once daily (n=117) or fluticasone furoate 100mcg once daily (n=112). Participants aged 5 to 11 years were randomly assigned to receive Breo Ellipta 50/25 mcg once daily (n=337) or fluticasone furoate 50mcg once daily (n=336).
The primary endpoint of the study was the weighted mean of forced expiratory volume in 1 second (FEV1) (0 to 4 hours) at week 12. Results showed that among patients 12 to 17 years of age, the difference in least squares (LS) mean change in FEV1 (0 to 4 hours) for Breo Ellipta 100/25mcg compared with fluticasone furoate 100mcg was 106mL (95% CI, -8, 220). In patients 5 to 11 years of age, the difference in LS mean change in FEV1 (0 to 4 hours) for Breo Ellipta 50/25mcg compared with fluticasone furoate 50mcg was 73mL (95% CI, 28-118).
As for safety, adverse reactions reported in at least 3% of pediatric patients treated with Breo Ellipta were nasopharyngitis (10%), upper respiratory tract infection (7%), allergic rhinitis (4%), rhinitis (3%), and headache (3%).
Breo Ellipta is supplied as a disposable light grey and pale blue plastic inhaler containing 2 foil strips, each with 30 blisters. In addition to the 100/25mcg and 200/25mcg dosage strengths, the FDA has approved a new 50mcg/25mcg dosage strength for pediatric patients aged 5 to 11 years.
This article originally appeared on MPR
References:
- Food and Drug Administration. FDA Letter: NDA 204275/S-022. Supplement approval: fulfillment of postmarketing requirement. US Food and Drug Administration. May 12, 2023. Accessed May 17, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/204275Orig1s022ltr.pdf.
- Breo Ellipta. Package insert. GlaxoSmithKline; 2023. Accessed May 17, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/204275s022lbl.pdf.
